Nootropic Peptides: Semax, Selank & the Evidence

"Nootropic peptides" is a marketing umbrella, not a pharmacological class. It groups together several short synthetic peptides promoted for memory, focus, mood or neuroprotection. The four most discussed are Semax and Selank (both developed in Russia and used there as prescription drugs), cerebrolysin (a porcine-brain-derived peptide mixture used in parts of Europe and Asia), and dihexa (an experimental angiotensin-IV-derived compound that has never reached the clinic).

What unites them is a shared pattern rather than a shared molecule: each has a plausible neurobiological mechanism, an enthusiastic online following, and a human evidence base that is far weaker than the confident marketing suggests. Understanding these peptides means separating three tiers of evidence that get routinely blurred together — in-vitro (cell-culture) data, animal studies, and controlled human trials.

This article is educational and is not medical advice. Several of these substances are prescription medicines in some countries and unapproved research chemicals in others. Nothing here is a recommendation to obtain or use them, and no dosing, sourcing or administration guidance is provided.

The defining feature of this field is that most of the clinical literature comes from Russia and neighboring countries, was published in regional-language journals, and has not been independently replicated by Western research groups. That is not automatically a reason to dismiss it — good science happens everywhere — but it does change how much weight a careful reader should assign.

The recurring methodological weaknesses in this literature include:

• Small sample sizes, often a few dozen participants.
• Frequent absence of randomization, blinding or placebo control.
• Composite or soft endpoints that are easy to move.
• Publication concentrated among groups with an interest in the compound.
• Limited independent replication outside the region of origin.

Cerebrolysin is the cautionary example that shows why replication matters. It is the most heavily studied peptide product of the group, yet when its trials were pooled and appraised by the independent Cochrane Collaboration, the enthusiastic regional picture did not hold up (detailed below). If the best-studied member of the family struggles under rigorous meta-analysis, healthy skepticism toward the thinner Semax, Selank and dihexa literature is warranted.

Semax is a synthetic heptapeptide analog of a fragment of ACTH (adrenocorticotropic hormone), specifically the ACTH(4-10) region, engineered for stability and devoid of the parent hormone's effects on the adrenal axis. It was developed in the Soviet Union and Russia and is on the Russian list of essential medicines for indications including ischemic stroke and cognitive disorders. It is typically given intranasally and is not approved in the United States or European Union.

Mechanistically, Semax has one of the more coherent stories in the field. A well-cited rat study published in Cellular and Molecular Neurobiology showed that after experimental cerebral ischemia, Semax upregulated the transcription of neurotrophins — including BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) — and, crucially, their high-affinity Trk receptors. The authors noted that ischemia normally downregulates these receptors even as neurotrophins rise, creating a mismatch; Semax appeared to promote concurrent upregulation of both, potentially letting stressed neurons actually respond to survival signals. This dual neurotrophic and receptor effect is the mechanistic backbone of most Semax claims.

The human evidence is thinner. Russian clinical studies in stroke patients report improvements on functional scales and shifts toward an anti-inflammatory profile, and some report increases in measurable plasma BDNF. But the strongest of these are often non-randomized or unblinded, which limits causal inference. For healthy cognitive enhancement — the use case most consumers care about — rigorous controlled human data are essentially absent. The honest summary: a strong, replicated animal mechanism; a modest, largely regional clinical signal in neurological injury; and no solid proof of nootropic benefit in healthy people.

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin, a naturally occurring immunomodulatory peptide. Like Semax it was developed in Russia, is used there as a prescription anxiolytic, is typically administered intranasally, and is not approved in the US or EU. Its headline claim is anxiety reduction comparable to benzodiazepines but without the sedation, dependence or withdrawal — with cognitive and mood benefits framed as secondary.

Selank's proposed mechanism is deliberately multi-target. Rather than binding the GABA-A receptor directly the way a benzodiazepine does, it appears to modulate GABAergic signaling indirectly. A study in Frontiers in Pharmacology found that Selank altered the expression of a large set of genes involved in GABAergic neurotransmission in rat brain, with effects that overlapped with but were not identical to GABA itself, and that additionally touched dopamine- and serotonin-related genes — consistent with allosteric, network-level modulation. Selank also inhibits enzymes that degrade enkephalins (endogenous opioid peptides) and has been reported to influence BDNF expression in the hippocampus, retaining some of tuftsin's immunomodulatory activity.

The human data center on a small number of Russian trials in generalized anxiety disorder and neurasthenia, generally reporting anxiolytic effects broadly similar to reference anxiolytics with fewer sedative side effects. These studies are small and were used to support regional regulatory approval, but they have not been replicated in large independent Western trials. As with Semax, the mechanism is interesting and multi-layered, but the claim of clean, benzodiazepine-like anxiety relief plus cognitive enhancement rests on a modest and geographically narrow evidence base.

Cerebrolysin is not a single peptide but a standardized mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain tissue. It is administered by injection or infusion and is marketed in numerous countries in Europe, Asia and Latin America for stroke, dementia and traumatic brain injury. Because it has been studied for decades, it offers the field's clearest test of whether the promising regional literature survives independent, rigorous appraisal.

The answer is sobering. A 2017 Cochrane systematic review of cerebrolysin for acute ischaemic stroke pooled six randomized trials in roughly 1,500 patients and found no difference in all-cause mortality and no demonstrated clinical benefit. The reviewers went further, identifying moderate-quality evidence of an increase in non-fatal serious adverse events with cerebrolysin, and concluded that routine use in acute ischaemic stroke is not supported by the evidence.

For vascular dementia the picture is marginally more favorable but still weak. A 2019 Cochrane review found that intravenous courses of cerebrolysin appeared to improve cognition and global function with no clear safety signal — but the authors stressed the data were not definitive, were undermined by heterogeneity and high risk of bias, and that any real benefit might be too small to be clinically meaningful. Their bottom line was that adequately powered, methodologically robust trials are still needed. Cerebrolysin thus embodies the central lesson of this article: an enthusiastic body of regional trials can shrink dramatically under independent meta-analysis.

Dihexa (developmental code PNB-0408) is an orally active, brain-penetrant oligopeptide derived from angiotensin IV, developed by Joseph Harding's group at Washington State University. Its notoriety comes from a striking laboratory claim: in a neurotrophic-activity assay it was reported to be roughly seven orders of magnitude more potent than BDNF at promoting synaptic connections. Its proposed mechanism is to bind hepatocyte growth factor (HGF) and potentiate its activity at the c-Met receptor, driving dendritic growth and synaptogenesis.

It is essential to be blunt about the evidence tier here: dihexa's cognitive data come entirely from animal models — for example, cognitive restoration in scopolamine-impaired and aged rodents. There are no published human efficacy trials of dihexa and no comprehensive human safety data. The eye-catching "ten-million-times-more-potent-than-BDNF" figure is an in-vitro potency measurement, not a statement about clinical benefit, and potency in a dish tells you nothing about whether a drug helps a person.

The most informative human data actually come from a relative, not dihexa itself. Fosgonimeton, a clinical-stage compound built on the same HGF/c-Met mechanism, was tested in the Phase 2/3 LIFT-AD trial in mild-to-moderate Alzheimer's disease. In 2024 the sponsor reported that the trial missed its primary endpoint (a global statistical test, p=0.70) and its key secondary cognitive and functional endpoints, with only directional trends and subgroup and biomarker signals to point to. That outcome is a direct caution against assuming the HGF/c-Met mechanism — however elegant in preclinical work — translates into measurable cognitive benefit in humans.

The single most useful habit when evaluating any nootropic peptide is to ask what tier of evidence a claim rests on. A compound can have a beautifully worked-out mechanism, dramatic effects in cell culture, and convincing rescue of deficits in rodents — and still do nothing measurable, or something harmful, in people. The history of neurology and psychiatry is full of agents that looked spectacular in animals and failed in humans; fosgonimeton's Phase 2/3 miss is a recent example on the very mechanism dihexa marketing celebrates.

A few principles for reading this literature honestly:

• Mechanism is a hypothesis, not a result. "Upregulates BDNF" or "activates c-Met" describes a plausible pathway, not a demonstrated clinical benefit.
• In-vitro potency numbers do not scale to human effect sizes. Being millions of times more potent than BDNF in an assay is a property of the assay, not a promise to your brain.
• Regional prescription approval is not equivalent to FDA/EMA approval. Different regulators apply different evidentiary bars.
• Absence of reported side effects in small, short studies is not the same as an established long-term safety profile.
• Independent replication is the currency that matters most, and it is precisely what most of this field still lacks.

These peptides are legitimately interesting scientific objects. Semax and Selank in particular have earned real mechanistic study, and cerebrolysin has generated genuinely large trials. But for the specific promise most consumers are sold — reliable cognitive enhancement in healthy people — the honest verdict is that the evidence is preliminary, geographically narrow, and not yet replicated to the standard that would justify confident claims. None of these agents is an approved cognitive enhancer, and several circulate in Western markets as unregulated research chemicals with unknown long-term risks.